-
Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC
•
Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its live bacteria therapeutic candidate KEX02, to be tested in combination with a PD-1 inhibitor for the treatment of non-small cell lung cancer (NSCLC). About KEX02KEX02…
-
Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate
•
Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga exclusive rights to research, develop, manufacture, and commercialize Sanyou’s in-house antibody drug candidate. Financial details of the deal were not disclosed. Agreement DetailsThe agreement builds on a previous licensing term list for two of Sanyou’s…
-
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
•
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of RMB 246 million (USD 36 million), a 142% year-on-year (YOY) increase. The growth was primarily driven by a 115% sales volume increase of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib, which was added to the…
-
Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform
•
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health…
-
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
•
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct both Phase I and Phase III clinical trials for ensifentrine, a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Partnership and DevelopmentThe drug…
-
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
•
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT trial has failed to meet primary endpoints, according to the firm’s Q2 2022 financial report and subsequent earnings call. The drug, approved in the US in February 2020 and in Europe in January 2022, saw…
-
Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022, with revenues reaching RMB 15.3 billion (USD 2.24 billion), up 20.17% year-on-year (YOY). Net profits rose 21.71% YOY to RMB 5.28 billion (USD 773 million). Business Segments R&D InvestmentMindray invested RMB 1.45 billion (USD 212…
-
JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products
•
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series B financing rounds, raising a total of RMB 700 million (USD 102.5 million). Investors include SinoRock, Guanghua Wutong Equity Investment Fund, YuanHengLiZhen, Weigao Holding, and HM Capital. The funding follows a Series A round led…
